Loading
Coya Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SNYDER DAVID S, was filed 14 Nov 2024.
Coya Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Coya Therapeutics, Inc. as filed with SEC (Form 4), a company from the Health Care sector. The past year has been quiet: not a single insider filing for Coya Therapeutics, Inc. The previous disclosure was published on 19 August 2025.
The full history, which starts in 2023, counts 12 purchases against no sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 7.9 m USD and net income at -21.2 m USD.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
14
Thresholds
n/a
Buy Volume
€103,122
12 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleArun Swaminathan2 buys
David S. Snyder1 buy
Fred Grossman1 buy
Since the insiders bought
- -7.4%Entry US$6.32 · Close at T+365 US$5.85
- -13.8%Entry US$6.81 · Close at T+365 US$5.87
- -17.7%Entry US$7.24 · Close at T+365 US$5.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Coya Therapeutics, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$15.21.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.22
Analyst consensus
7 analystsStrong buy
US$12.00Target US$15.21(+261%)US$18.00
Income statement
RevenueUS$7.9M
EBITDA-US$22.5M-284% margin
Net income-US$21.2M-270.2% margin
Valuation
PER (forward)-2.2x
P/Book2.3x
Beta0.58
Balance sheet & cash
Market capUS$99M
Total debtUS$13M
Free Cash Flow-US$10.7M
Profitability & ownership
ROE-60.5%
ROA-32.3%
% insiders14.7%
% institutions33.3%
Last declaration on 19 August 2025
Declarations14 total
17,557 shares@ US$1.09100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001641172-25-024820:0
1,800 shares@ US$7.1858100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-24-046106:0
Canonical exit: 12 Feb 2025 (T+90)
5,000 shares@ US$7.359450.3% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-24-045120:0
Canonical exit: 11 Feb 2025 (T+90)
5,000 shares@ US$7.337849.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-24-044819:0
Canonical exit: 9 Feb 2025 (T+90)
2,710 shares@ US$7.37100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-24-044896:0
Canonical exit: 9 Feb 2025 (T+90)
1,000 shares@ US$3.62100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-24-008916:0
Canonical exit: 20 Nov 2023 (T+90)
6,479 shares@ US$4.0087.9% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-23-000226:1
2,000 sharesCommon Stock, par value $0.0001 per shareSEC:0001493152-23-000223:0
Canonical exit: 3 Apr 2023 (T+90)
10,000 sharesCommon Stock, par value $0.0001 per shareSEC:0001493152-23-000221:0
Canonical exit: 3 Apr 2023 (T+90)
10,000 sharesCommon Stock, par value $0.0001 per shareSEC:0001493152-23-000222:0
Canonical exit: 3 Apr 2023 (T+90)
7,000 sharesCommon Stock, par value $0.0001 per shareSEC:0001493152-23-000224:0
Canonical exit: 3 Apr 2023 (T+90)
10,000 sharesCommon Stock, par value $0.0001 per shareSEC:0001493152-23-000227:0
Canonical exit: 3 Apr 2023 (T+90)
10,000 sharesCommon Stock, par value $0.0001 per shareSEC:0001493152-23-000226:0
Canonical exit: 3 Apr 2023 (T+90)
10,000 sharesCommon Stock, par value $0.0001 per shareSEC:0001493152-23-000225:0
Canonical exit: 3 Apr 2023 (T+90)
14 of 14 declarations
About Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. It concentrates on research and commercialization of treatments that enhance the quality of life for patients.
